Viral conjunctivitis is the inflammation of the conjunctiva of viral etiology.
Signs and symptoms include unilateral or bilateral eye redness, foreign body sensation and follicular conjunctival reaction.
It may be caused by adenovirus, herpes simplex or molluscum contagiosum.
Tabbara KF, Hyndiuk, RA. Infections of the eye. 2nd ed. Boston: Little, Brown and Company; 1996:453-470
Caparas VL, Dy-Liacco JU, Espiritu CG, et al. Handbook of cornea and external diseases: Cornea Club of the Philippines; 2000
Weisbecker CA, Fraunfelder FT, Tipperman R. Physicians' desk reference for ophthalmic medicines. Montvale: Medical Economics Company Inc; 2002
Rhee DJ, Pyfer MF. The Wills eye manual: office and emergency room diagnosis and treatment of eye disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1999:121-122
American Academy of Ophthalmology Preferred Practice Patterns Committee Cornea/External Disease Panel. Preferred practice pattern: conjunctivitis. San Francisco: American Academy of Ophthalmology; 2003
American Academy of Ophthalmology Preferred Practice Patterns Committee Cornea/External Disease Panel. Preferred practice pattern: conjunctivitis. San Francisco: American Academy of Ophthalmology. 2003
Jacobs DS. Conjunctivitis. UpToDate. http://www.uptodate.com/contents/conjunctivitis. 16 Oct 2012. Accessed 14 Feb 2014
American Academy of Ophthalmology Cornea/External Disease PPP Panel, Hoskins Center for Quality Eye Care. Conjunctivitis Summary Benchmark – 2013. ONE Network. http://one.aao.org/summary-benchmark-detail/conjunctivitis-summary-benchmark--october-2012. Oct 2013. Accessed 14 Feb 2014
Alfonso SA, Fawley JD, Lu XA. Conjunctivitis. Primary Care: Clinics in Office Practice. 2015 Sep;42(3):325-345. http://dx.doi.org/10.1016/j.pop.2015.05.001.
Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.